FR901228
Jump to navigation
Jump to search
| FR901228 | |
|---|---|
| Term | FR901228 |
| Short definition | FoundationOne CDx test (Fown-DAY-Avoid…) A laboratory test performed on a sample of tumor tissue to match a patient's tumor to a specific drug or therapy. A FoundationOne CDx test looks at many different genes in the tissue sample to determine if a patient's tumor has a specific gene mutation (change) or biomarker that is targeted by a specific drug or therapy. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
FR901228 - A drug used to treat adults with cutaneous T-cell lymphoma who have been previously treated with at least one other systemic therapy. It is also being studied in the treatment of other types of cancer. FR901228 blocks certain enzymes needed for cell division and can kill cancer cells. It's a type of depsipeptide and a type of histone deacetylase inhibitor. Also called Istodax and Romidepsin
External links
- Medical encyclopedia article on FR901228
- Wikipedia's article - FR901228
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski